230 related articles for article (PubMed ID: 38291285)
1. Does Systemic Anti-Psoriatic Treatment Impact the Risk of Cardiovascular Disease? A Review Over Cardiovascular Imaging Studies.
Kaiser H; Näslund-Koch C; Kvist-Hansen A; Skov L
Dermatol Ther (Heidelb); 2024 Feb; 14(2):303-321. PubMed ID: 38291285
[TBL] [Abstract][Full Text] [Related]
2. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
3. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
4. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
[TBL] [Abstract][Full Text] [Related]
5. Cardiometabolic Disorders in Psoriatic Disease.
Sobchak C; Eder L
Curr Rheumatol Rep; 2017 Aug; 19(10):63. PubMed ID: 28844116
[TBL] [Abstract][Full Text] [Related]
6. Omega-3 Fatty Acids and Cardiovascular Disease: An Updated Systematic Review.
Balk EM; Adams GP; Langberg V; Halladay C; Chung M; Lin L; Robertson S; Yip A; Steele D; Smith BT; Lau J; Lichtenstein AH; Trikalinos TA
Evid Rep Technol Assess (Full Rep); 2016 Aug; (223):1-1252. PubMed ID: 30307737
[TBL] [Abstract][Full Text] [Related]
7. IL-17 Pathway Members as Potential Biomarkers of Effective Systemic Treatment and Cardiovascular Disease in Patients with Moderate-to-Severe Psoriasis.
Wang X; Kaiser H; Kvist-Hansen A; McCauley BD; Skov L; Hansen PR; Becker C
Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008981
[TBL] [Abstract][Full Text] [Related]
8. Psoriasis and cardiovascular disease: the elusive link.
Manolis AA; Manolis TA; Melita H; Manolis AS
Int Rev Immunol; 2019; 38(1):33-54. PubMed ID: 30457023
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. Psoriasis and Vascular Risk : An Update.
Katsiki N; Anagnostis P; Athyros VG; Karagiannis A; Mikhailidis DP
Curr Pharm Des; 2014; 20(39):6114-25. PubMed ID: 24745923
[TBL] [Abstract][Full Text] [Related]
11. Biologics for Reducing Cardiovascular Risk in Psoriasis Patients.
Terui H; Asano Y
J Clin Med; 2023 Feb; 12(3):. PubMed ID: 36769825
[TBL] [Abstract][Full Text] [Related]
12. PET/CT-Based Characterization of 18F-FDG Uptake in Various Tissues Reveals Novel Potential Contributions to Coronary Artery Disease in Psoriatic Arthritis.
Schwartz DM; Parel P; Li H; Sorokin AV; Berg AR; Chen M; Dey A; Hong CG; Playford M; Sylvester M; Teague H; Siegel E; Mehta NN
Front Immunol; 2022; 13():909760. PubMed ID: 35720288
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Specialist and Patient Perspectives on Strategies to Improve Cardiovascular Disease Prevention Among Persons With Psoriatic Disease.
Barbieri JS; Beidas RS; Gondo GC; Fishman J; Williams NJ; Armstrong AW; Ogdie AR; Mehta N; Gelfand JM
JAMA Dermatol; 2022 Mar; 158(3):252-259. PubMed ID: 35044419
[TBL] [Abstract][Full Text] [Related]
14. GlycA Is a Novel Biomarker of Inflammation and Subclinical Cardiovascular Disease in Psoriasis.
Joshi AA; Lerman JB; Aberra TM; Afshar M; Teague HL; Rodante JA; Krishnamoorthy P; Ng Q; Aridi TZ; Salahuddin T; Natarajan B; Lockshin BN; Ahlman MA; Chen MY; Rader DJ; Reilly MP; Remaley AT; Bluemke DA; Playford MP; Gelfand JM; Mehta NN
Circ Res; 2016 Nov; 119(11):1242-1253. PubMed ID: 27654120
[TBL] [Abstract][Full Text] [Related]
15. From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.
Hugh J; Van Voorhees AS; Nijhawan RI; Bagel J; Lebwohl M; Blauvelt A; Hsu S; Weinberg JM
J Am Acad Dermatol; 2014 Jan; 70(1):168-77. PubMed ID: 24184141
[TBL] [Abstract][Full Text] [Related]
16. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study.
Boehncke S; Salgo R; Garbaraviciene J; Beschmann H; Hardt K; Diehl S; Fichtlscherer S; Thaçi D; Boehncke WH
J Eur Acad Dermatol Venereol; 2011 Oct; 25(10):1187-93. PubMed ID: 21241371
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review.
Horreau C; Pouplard C; Brenaut E; Barnetche T; Misery L; Cribier B; Jullien D; Aractingi S; Aubin F; Joly P; Le Maître M; Ortonne JP; Paul C; Richard MA
J Eur Acad Dermatol Venereol; 2013 Aug; 27 Suppl 3():12-29. PubMed ID: 23845149
[TBL] [Abstract][Full Text] [Related]
18. Urinary orosomucoid: a new marker of cardiovascular risk in psoriatic patients?
Németh B; Péter I; Boncz I; Jagicza A; Kiss I; Csergő Á; Kőszegi T; Kustán P; Horváth IG; Ajtay Z
Ther Clin Risk Manag; 2019; 15():831-837. PubMed ID: 31308681
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
